Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/22/2005WO2005121078A2 Substituted cyclopentene compounds
12/22/2005WO2005121076A1 (diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
12/22/2005WO2005121074A2 Processes for the preparation of sertraline hydrochloride
12/22/2005WO2005121071A1 Process for the preparation of nateglinide
12/22/2005WO2005121070A1 Levodopa prodrugs, and compositions and uses thereof
12/22/2005WO2005121069A1 Levodopa prodrugs, and compositions and uses thereof
12/22/2005WO2005121065A2 DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
12/22/2005WO2005121061A1 Novel process for producing ibuprofen sodium dihydrate
12/22/2005WO2005120643A2 Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms
12/22/2005WO2005120642A2 Tetrahydropyridothiophenes for treating hyperproliferative disorders
12/22/2005WO2005120638A1 Combination of radio waves and pharmacologically active substances
12/22/2005WO2005120588A2 Peptides delivered to cell nuclei
12/22/2005WO2005120583A2 Method for preventing or treating cardiac hypertrophy
12/22/2005WO2005120582A2 Compositions and methods for inhibiting expression of hypoxia-inducible genes
12/22/2005WO2005120578A2 Biodegradable drug-polymer delivery system
12/22/2005WO2005120576A2 Composition and method for improving pancreatic islet cell survival
12/22/2005WO2005120574A1 Drug having regulatory cell ligand contained in liposome
12/22/2005WO2005120573A2 Cationic bacteriochlorophyll derivatives and uses thereof
12/22/2005WO2005120572A1 Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied hydrophobic green porphyrins
12/22/2005WO2005120563A2 Induction of an immune response against streptococcus pneumoniae polysaccharides
12/22/2005WO2005120544A1 Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition therefor in form of a kit
12/22/2005WO2005120539A2 Novel use of peptide compounds for treating pain in trigeminal neuralgia
12/22/2005WO2005120535A1 Composition comprising ginsenosides for treating or preventing angiostenosis and restenosis
12/22/2005WO2005120524A2 Nutritional formulations
12/22/2005WO2005120523A1 Methods and compositions for treating mood disorder
12/22/2005WO2005120521A2 Methods of treating cancer with 8-chloro-adenosine
12/22/2005WO2005120520A2 Compositions and methods for diagnosis and treatment of chemotherapy-resistant neoplastic disease
12/22/2005WO2005120519A1 Glycosylphosphatidylinositol glycan signalling via integrins functioning as glycan specific receptors
12/22/2005WO2005120518A2 Use of atp analogues for treatment of cardiovascular diseases
12/22/2005WO2005120517A1 Stable liquid suspension formulation comprising synthetic steroids and process for producing the same
12/22/2005WO2005120516A2 Hiv integrase inhibitors
12/22/2005WO2005120515A2 Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease
12/22/2005WO2005120514A1 Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
12/22/2005WO2005120513A1 Protein kinase inhibitors
12/22/2005WO2005120512A2 Cancer treatment method
12/22/2005WO2005120511A1 Methods for treating mast cell disorders
12/22/2005WO2005120510A1 Quinazolinone derivatives useful as vanilloid antagonists
12/22/2005WO2005120509A1 Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
12/22/2005WO2005120508A1 Benzothiazole antiviral agents
12/22/2005WO2005120507A1 Opioids for the treatment of the chronic obstructive pulmonary disease (copd)
12/22/2005WO2005120506A1 Opioids for the treatment of the restless leg syndrome
12/22/2005WO2005120505A2 Tetrahydropyranyl cyclopentyl tetrahy-dropyridopyridine modulators of chemokine receptor activity
12/22/2005WO2005120504A2 Cancer treatment method
12/22/2005WO2005120503A2 N-aryl piperidine compounds for inhibiting hiv infection
12/22/2005WO2005120502A1 New pharmaceutical composition and process for the preparation thereof
12/22/2005WO2005120501A1 Method of bowel cleansing
12/22/2005WO2005120500A2 Sleeves for accommodating a circulation enhancement device
12/22/2005WO2005120499A1 Form a of valdecoxib suitable for pharmaceutical formulations
12/22/2005WO2005120498A2 Method for synthesis of lonidamine and related indazole derivatives
12/22/2005WO2005120497A2 Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
12/22/2005WO2005120496A2 TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE
12/22/2005WO2005120495A1 Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
12/22/2005WO2005120494A1 1-`(3r)-amino-4-(2-fluoro-phenyl)-butyl !-pyrrolidine-(2r)-carboxilic acid-benzyl amine derivatives and related compounds as dipeptidyl-peptidase iv (dpp-iv) inhibitors for the treatment of type 2 diabetes mellitus
12/22/2005WO2005120493A1 Anticancer effect enhancer
12/22/2005WO2005120492A1 Counteracting drug-induced obesity using glp-1 agonists
12/22/2005WO2005120491A1 Remedy or preventive for inflammatory bowel disease
12/22/2005WO2005120490A1 Capsule stable against mastication
12/22/2005WO2005120489A2 Treatment of central nervous system disorders or injuries with d-methionine
12/22/2005WO2005120488A1 Aspartic acid for the regeneration of bone matter
12/22/2005WO2005120487A2 Preparation for the prevention and treatment of stress conditions as well as functional and organic disorders of the nervous system and metabolic disorders
12/22/2005WO2005120486A2 Novel use of cytotoxic drugs for treatment and prophylasxis of aging diseases by reversing the loss of elasticity of epithelial cells due to aging
12/22/2005WO2005120485A1 Regulator of physiological function of ghrelin and use thereof
12/22/2005WO2005120484A1 Regulator for physiological functions of ghrelin
12/22/2005WO2005120483A2 Selective androgen receptor modulators and methods of use thereof
12/22/2005WO2005120482A1 System and method for transdermal delivery of an anticoagulant
12/22/2005WO2005120481A1 Propafenone hydrochloride capsules containing microtablets
12/22/2005WO2005120480A1 Antitumor effect fortifier, antitumor agent and method of therapy for cancer
12/22/2005WO2005120479A1 Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
12/22/2005WO2005120478A1 Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
12/22/2005WO2005120477A2 N- (2-benzyl) -2-phenylbutanamides as androgen receptor modulators
12/22/2005WO2005120476A2 Novel use of peptide compounds for treating amyotrophic lateral sclerosis
12/22/2005WO2005120475A2 Pharmaceutical composition for the treatment of bacterial infections and sepsis
12/22/2005WO2005120474A2 Phophodiesterase 10a inhibitors to amplify the action of glp1-mimetics or dpp-iv inhibitors in diabetes
12/22/2005WO2005120472A1 Self-heating pharmaceutical patch
12/22/2005WO2005120470A1 Matrix-controlled transdermal therapeutic system based on an adhesive for administering norelgestromin or the combination thereof with an estrogen
12/22/2005WO2005120467A2 Dosage form containing the active ingredient cholylsarcosine
12/22/2005WO2005120466A2 Sugar coatings and methods therefor
12/22/2005WO2005120465A2 Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines
12/22/2005WO2005120463A1 Rapidly disintegrating tablets of risperidone
12/22/2005WO2005120460A1 Sterol enriched mixed lammelarity amphotericin intercalating liposomes in saline and the process for their preparation
12/22/2005WO2005120457A1 Immune enhancing compositions and methods of use thereof
12/22/2005WO2005120456A2 Formulation of eletriptan
12/22/2005WO2005120451A1 Method of decreasing sebum production and pore size
12/22/2005WO2005120436A2 Composition for treating post-surgical pain
12/22/2005WO2005120435A2 Method for preparing sustained release compositions and the use of said compositions for treating chronic diseases of central nervous system (cns)
12/22/2005WO2005120432A1 Dispenser for progestin used for acute and maintenance treatment of dub
12/22/2005WO2005120148A2 Compounds derived from lidocaine, pharmaceutical compositions, use and method of treatment, prevention or inhibition of diseases
12/22/2005WO2005113537A3 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
12/22/2005WO2005111031A3 Neuropeptide receptor modulators
12/22/2005WO2005108337A3 Compounds with activity at estrogen receptor
12/22/2005WO2005107767A3 Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
12/22/2005WO2005105106A3 Hormone treatment of macular degeneration
12/22/2005WO2005102999A3 Crystalline forms of fexofenadine hydrochloride and processes for their preparation
12/22/2005WO2005102366A3 Lithium combinations, and uses related thereto
12/22/2005WO2005100340A3 Polycyclic pyridines as potassium ion channel modulators
12/22/2005WO2005099716A3 Method for analyzing the biological age of a subject
12/22/2005WO2005099702A3 R(-)-11-hydroxyaporphine derivatives and uses thereof
12/22/2005WO2005097814A3 Composition and method for inhibiting platelet aggregation
12/22/2005WO2005097123A3 Pyridyl-substituted porphyrin compounds and methods of use thereof
12/22/2005WO2005097098A3 Use of ppr delta agonists for treating demyelinating diseases
1 ... 4423 4424 4425 4426 4427 4428 4429 4430 4431 4432 4433 4434 4435 4436 4437 4438 4439 4440 4441 4442 4443 ... 7860